The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa

被引：41

作者：

Frank, Guido K. W. ^{[1
,2
]}

Shott, Megan E. ^{[1
]}

Hagman, Jennifer O. ^{[1
]}

Schiel, Marissa A. ^{[1
]}

DeGuzman, Marisa C. ^{[1
,2
]}

Rossi, Brogan ^{[1
]}

机构：

[1] Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO 80045 USA

[2] Univ Colorado, Dept Neurosci, Anschutz Med Campus, Aurora, CO 80045 USA

来源：

INTERNATIONAL JOURNAL OF EATING DISORDERS | 2017年 / 50卷 / 04期

关键词：

anorexia nervosa; aripiprazole; dopamine; eating disorder; medication; receptor; treatment; weight gain;

D O I：

10.1002/eat.22704

中图分类号：

B849 [应用心理学];

学科分类号：

040203 ;

摘要：

ObjectiveFinding medication to support treatment of anorexia nervosa has been difficult. Neuroscience-based approaches may help in this effort. Recent brain imaging studies in adults and adolescents with anorexia nervosa suggest that dopamine-related reward circuits are hypersensitive and could provide a treatment target. MethodsHere, we present a retrospective chart review of 106 adolescents with anorexia nervosa some of whom were treated with the dopamine D2 receptor partial agonist aripiprazole during treatment in a specialized eating disorder program. ResultsThe results show that aripiprazole treatment was associated with greater increase in body mass index (BMI) during treatment. DiscussionThe use of dopamine receptor agonists may support treatment success in anorexia nervosa and should be further investigated.

引用

页码：447 / 450

页数：4

共 50 条

[31] Interactions of the novel antipsychotic, aripiprazole, at the D2 dopamine receptor.
Prioleau, C
Lawler, CP
Mailman, RB
FASEB JOURNAL, 1998, 12 (04): : A456 - A456
[32] Effects of Dopamine D2 Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-11C]DOPA
Ito, Hiroshi
Takano, Harumasa
Arakawa, Ryosuke
Takahashi, Hidehiko
Kodaka, Fumitoshi
Takahata, Keisuke
Nogami, Tsuyoshi
Suzuki, Masayuki
Suhara, Tetsuya
PLOS ONE, 2012, 7 (09):
[33] The dopamine-serotonin system stabilizer aripiprazole is a partial agonist at D2 and 5-HT1A receptors
Jordan, S
Robert, MD
Frank, YD
Tetsuro, K
BIOLOGICAL PSYCHIATRY, 2003, 53 (08) : 183S - 183S
[34] Discovery of a true bivalent dopamine D2 receptor agonist
Qian, Mingcheng
Ricarte, Adrian
Wouters, Elise
Dalton, James A. R.
Risseeuw, Martijn D. P.
Giraldo, Jesus
Van Calenbergh, Serge
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 212
[35] VANADATE INHIBITS AGONIST BINDING TO D2 DOPAMINE RECEPTOR
ELAZAR, Z
FUCHS, S
JOURNAL OF MOLECULAR NEUROSCIENCE, 1991, 3 (01) : 1 - 6
[36] Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist
Xu, Jinbin
Vangveravong, Suwanna
Li, Shihong
Fan, Jinda
Jones, Lynne A.
Cui, Jinquan
Wang, Ruike
Tu, Zhude
Chu, Wenhua
Perlmutter, Joel S.
Mach, Robert H.
NEUROIMAGE, 2013, 71 : 168 - 174
[37] TERGURIDE, A DOPAMINE D2 PARTIAL AGONIST, AS A DISCRIMINATIVE STIMULUS IN RATS
YAMAGUCHI, M
KIMURAIWASAKI, K
AKAI, T
NAKADA, Y
NAKAGAWA, H
BEHAVIOURAL PHARMACOLOGY, 1991, 2 (03): : 233 - 240
[38] Early Weight Gain Predicts Outcome in Two Treatments for Adolescent Anorexia Nervosa
Le Grange, Daniel
Accurso, Erin C.
Lock, James
Agras, Stewart
Bryson, Susan W.
INTERNATIONAL JOURNAL OF EATING DISORDERS, 2014, 47 (02) : 124 - 129
[39] Assessment of brain function in adolescent anorexia nervosa before and after weight gain
Bradley, SJ
Taylor, MJ
Rovet, JF
Goldberg, E
Hood, J
Wachsmuth, R
Azcue, MP
Pencharz, PB
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 1997, 19 (01) : 20 - 33
[40] STATE-DEPENDENT EFFECTS OF D2 PARTIAL AGONIST ARIPIPRAZOLE ON DOPAMINE NEURON ACTIVITY IN THE MAM NEURODEVELOPMENTAL MODEL OF SCHIZOPHRENIA
Sonnenschein, Susan
Gill, Kathryn
Grace, Anthony
SCHIZOPHRENIA BULLETIN, 2018, 44 : S338 - S338

← 1 2 3 4 5 →